In vitro blood-brain barrier model adapted to repeated-dose toxicological screening

Toxicology in Vitro

Volumn 27, Issue 6, 2013, Pages 1944-1953

  Fabulas da Costa, A ^a,b   Aijjou, R ^a,b   Hachani, J ^a,b   Landry, C ^a,b   Cecchelli, R ^a,b   Culot, M ^a,b  

^a UNIV LILLE   (France)

^b EA 2465   (France)

Author keywords

Blood brain barrier; Chronic toxicity; Colchicine; Endothelial cells; In vitro model

Indexed keywords

AMIODARONE; BUFLOMEDIL; CARBAMAZEPINE; CHLORPROMAZINE; CIPROFLOXACIN; CISPLATIN; COLCHICINE; CYCLOSPORIN A; DIAZEPAM; LOPERAMIDE; NADOLOL; ONDANSETRON; PROPOFOL;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; COW; DRUG ACCUMULATION; DRUG REEXPOSURE; ENDOTHELIUM CELL; GLIA CELL; IN VITRO STUDY; MODEL; NEUROTOXICITY; NEWBORN; NONHUMAN; RAT; TOXICITY TESTING;

BLOOD-BRAIN BARRIER; CHRONIC TOXICITY; COLCHICINE; ENDOTHELIAL CELLS; IN VITRO MODEL;

ANIMALS; ANIMALS, NEWBORN; BLOOD-BRAIN BARRIER; CATTLE; CELLS, CULTURED; COCULTURE TECHNIQUES; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDOTHELIAL CELLS; NEUROGLIA; RATS; RATS, SPRAGUE-DAWLEY; TOXICITY TESTS;

EID: 84880934143     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2013.06.026     Document Type: Article

References (36)

1. Anderson P.O., Knoben J.E., Troutman W.G. Handbook of clinical drug data. tenth ed. Can. Med. Assoc. J. 2002, 128:1357.
2. Balls M., Goldberg A.M., Fentem J.H., Broadhead C.L., Burch R.L., Festing M.F.W., Frazier J.M., Hendriksen C.F., Jennings M., Van der Kamp M.D., Morton D.B., Rowan A.N., Russell C., Russell W.M., Spielmann H., Stephens M.L., Stokes W.S., Straughan D.W., Yager J.D., Zurlo J., van Zutphen B.F. The three Rs: the way forward: the report and recommendations of ECVAM Workshop 11. ATLA. Altern. Lab. Anim. 1995, 23:838-866.
3. Bal-Price A.K., Hogberg H.T., Buzanska L., Lenas P., Van Vliet E., Hartung T. In vitro developmental neurotoxicity (DNT) testing: relevant models and endpoints. Neurotoxicology 2010, 31:545-554.
4. Bell D.N., Liu J.J., Tingle M.D., Rattel B., Meyer T.U., McKeage M.J. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro. Clin. Exp. Pharmacol. Physiol. 2008, 35:1440-1446.
5. Benet L.Z., Broccatelli F., Oprea T.I. BDDCS applied to over 900 drugs. AAPS J. 2011, 13:519-547.
6. Berezowski V., Landry C., Dehouck M.-P., Cecchelli R., Fenart L. Contribution of glial cells and pericytes to the mRNA profiles of P-glycoprotein and multidrug resistance-associated proteins in an in vitro model of the blood-brain barrier. Brain Res. 2004, 1018:1-9.
7. Booher J., Sensenbrenner M. Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiology 1972, 2:97-105.
8. Cecchelli R., Berezowski V., Lundquist S., Culot M., Renftel M., Dehouck M.-P., Fenart L. Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug Discovery 2007, 6:650-661.
9. Centers for Disease Control and Prevention (CDC) Deaths from intravenous colchicine resulting from a compounding pharmacy error - Oregon and Washington. Morbidity Mortality Weekly Rep. 2007, 56:1050-1052.
10. Chen L., Zhang B., Toborek M. Autophagy is involved in nanoalumina-induced cerebrovascular toxicity. Nanomedicine 2013, 9:212-221.
11. Clissold S.P., Lynch S., Sorkin E.M. Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs 1987, 33:430-460.
12. Coecke S., Ahr H., Blaauboer B.J., Bremer S., Casati S., Castell J., Combes R., Corvi R., Crespi C.L., Cunningham M.L., Elaut G., Eletti B., Freidig A., Gennari A., Ghersi-Egea J.F., Guillouzo A., Hartung T., Hoet P., Ingelman-Sundberg M., Munn S., Janssens W., Ladstetter B., Leahy D., Long A., Meneguz A., Monshouwer M., Morath S., Nagelkerke F., Pelkonen O., Ponti J., Prieto P., Richert L., Sabbioni E., Schaack B., Steiling W., Testai E., Vericat J.A., Worth A. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern. Lab. Anim. 2006, 34:49-84.
13. Culot M., Lundquist S., Vanuxeem D., Nion S., Landry C., Delplace Y., Dehouck M.-P., Berezowski V., Fenart L., Cecchelli R. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. Toxicol. In vitro. 2008, 22:799-811.
14. Dauchy S., Dutheil F., Weaver R.J., Chassoux F., Daumas-Duport C., Couraud P.-O., Scherrmann J.-M., Declèves X. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J. Neurochem. 2008, 107:1518-1528.
15. De Lannoy I., Mandin R., Silverman M. Renal secretion of vinblastine, vincristine and colchicine in vivo. J. Pharmacol. Exp. Ther. 1994, 268:388-395.
16. Dehouck M.P., Méresse S., Delorme P., Fruchart J.C., Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J. Neurochem. 1990, 54:1798-1801.
17. Eyal S., Hsiao P., Unadkat J.D. Drug interactions at the blood-brain barrier: fact or fantasy?. Pharmacol. Ther. 2009, 123:80-104.
18. Fauquette W., Amourette C., Dehouck M.-P., Diserbo M. Radiation-induced blood-brain barrier damages: an in vitro study. Brain Res. 2012, 1433:114-126.
19. Fridén M., Ljungqvist H., Middleton B., Bredberg U., Hammarlund-Udenaes M. Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J. Cereb. Blood Flow Metab. 2010, 30:150-161.
20. Ghosh C., Marchi N., Desai N.K., Puvenna V., Hossain M., Gonzalez-Martinez J., Alexopoulos A.V., Janigro D. Cellular localization and functional significance of CYP3A4 in the human epileptic brain. Epilepsia 2011, 52:562-571.
21. Hallier-Vanuxeem D., Prieto P., Culot M., Diallo H., Landry C., Tähti H., Cecchelli R. New strategy for alerting central nervous system toxicity: integration of blood-brain barrier toxicity and permeability in neurotoxicity assessment. Toxicol. In vitro. 2009, 23:447-453.
22. Hamm S., Dehouck B., Kraus J., Wolburg-Buchholz K., Wolburg H., Risau W., Cecchelli R., Dehouck M.-P. Astrocyte mediated modulation of blood-brain barrier permeability does not correlate with a loss of tight junction proteins from the cellular contacts. Cell Tissue Res. 2004, 315:157-166.
23. Levy M., Spino M., Read S.E. Colchicine: a state-of-the-art review. Pharmacotherapy 1991, 11:196-211.
24. Lippmann E.S., Azarin S.M., Kay J.E., Nessler R.A., Wilson H.K., Al-Ahmad A., Palecek S.P., Shusta E.V. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat. biotechnol. 2012, 30:783-791.
25. Llorens J., Li A.A., Ceccatelli S., Suñol C. Strategies and tools for preventing neurotoxicity: to test, to predict and how to do it. Neurotoxicology 2012, 33:796-804.
26. Namikawa K., Asakura M., Minami T., Okazaki Y., Kadota E., Hashimoto S. Toxicity of cisplatin to the central nervous system of male rabbits. Biol. Trace Elem. Res. 2000, 74:223-235.
27. Niel E., Scherrmann J.-M. Colchicine today. Joint, Bone, Spine 2006, 73:672-678.
28. Sugimoto S., Yamamoto Y.L., Nagahiro S., Diksic M. Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats. J. Neuro-Oncol. 1995, 24:229-240.
29. Terkeltaub R.A., Furst D.E., Digiacinto J.L., Kook K.A., Davis M.W. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011, 63:2226-2237.
30. Urich E., Lazic S.E., Molnos J., Wells I., Freskgård P.-O. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS ONE 2012, 7:e38149.
31. Van der Sandt I.C., Gaillard P.J., Voorwinden H.H., De Boer A.G., Breimer D.D. P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier. Pharm. Res. 2001, 18:587-592.
32. Wason S., Digiacinto J.L., Davis M.W. Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects. Postgrad. med. 2012, 124:189-196.
33. Yang S.H., Lee M.G. Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability. Biopharm. Drug Dispos. 2008, 29:414-426.
34. Youdim K.A., Qaiser M.Z., Begley D.J., Rice-Evans C.A., Abbott N.J. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med. 2004, 36:592-604.
35. Zhang B., Chen L., Choi J.J., Hennig B., Toborek M. Cerebrovascular toxicity of PCB153 is enhanced by binding to silica nanoparticles. J. Neuroimmune Pharmacol. 2012, 7:991-1001.
36. Zhang, F., Xue, J., Shao, J., Jia, L., 2012. Compilation of 222 drugs' plasma protein binding data and guidance for study designs. Drug Discov. Today 17, 475-485. http://www.drugbank.ca